Trigemina Presents Data on Intranasal Oxytocin for the Treatment of Trigeminal Neuralgia

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MORAGA, Calif., Aug. 29, 2013 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, announced that David C. Yeomans, Ph.D., Chief Scientist and Founder of Trigemina, as well as the Director of Pain Research at Stanford University School of Medicine, presented at the 2013 Napa Pain Conference on August 23rd – 25th, 2013 in Napa, California.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC